Investors

Events & Presentations

Upcoming Events

Details on upcoming events are not yet available. Please click here to be notified of all upcoming events.

Presentations
Date Title
Mar 6, 2017
Archived Events
Date Event Details
Mar 14, 2017
8:30 AM PT
29th Annual ROTH Conference
Feb 8, 2017
4:30 PM ET
Second Quarter Financial Results Conference Call and Webcast
Dec 14, 2016
3:20 PM ET
BMO Capital Markets Prescriptions for Success Healthcare Conference
Nov 15, 2016
3:45 PM ET
Stifel 2016 Healthcare Conference
Nov 8, 2016
5:00 PM ET
First Quarter Financial Results Conference Call and Webcast
Sep 12, 2016
5:00 PM
Fourth Quarter and Fiscal Year Financial Results Conference Call and Webcast
Aug 16, 2016
1:20 PM ET
Wedbush PacGrow Healthcare Conference
Jul 13, 2016
11:45 AM ET
Cantor Fitzgerald 2nd Annual Healthcare Conference
Jun 27–28, 2016
Ocular Toxicology, Pharmacology and Drug Delivery: An Eye on the Future
Jun 21, 2016
Research Day
New York
Jun 1, 2016
1:30 PM ET
Boston CEO Conference

AGTC President & CEO Sue Washer will be participating in a panel discussion entitled "Genetic Therapies: The promise and the challenge" from 1:30 — 2:00 p.m. EDT 

May 17, 2016
3:50 PM ET
Piper Jaffray GenomeRx Symposium
New York

AGTC President & CEO Sue Washer will be participating in a panel discussion entitled "Eyes on Gene Therapy For Ophthalmology" from 3:50 — 4:25 p.m. EDT

May 9, 2016
5:00 PM ET
Third Quarter Financial Results Conference Call and Webcast
May 4–7, 2016
American Society of Gene & Cell Therapy (ASGCT) 19th Annual Meeting

Terence R. Flotte, M.D., Celia and Isaac Haidak Professor in Medical Education and dean of the University of Massachusetts School of Medicine, presented new clinical data evaluating the use of recombinant AAV-AAT vector gene delivery to muscle in patients with alpha-1-antitrypsin (AAT) deficiency, an inherited genetic disorder that results in severe loss of lung function caused by complete or partial deficiency of the alpha-1 antitrypsin protein. The abstract is titled "Sustained Expression with Partial Correction of Neutrophil Defects 5 Years after Intramuscular rAAV1 Gene Therapy for Alpha-1 Antitrypsin Deficiency."

AGTC President & CEO Sue Washer was co-chair of the ASGCT Commercialization Workshop.

AGTC also presented three abstracts supporting its investigational gene therapies in the treatment of rare inherited disease:

  • “Safety and Biodistribution Study of rAAV2tYF-PR1.7-hCNGB3 in Nonhuman Primates,” presented by Paulette M. Robinson, Ph.D., AGTC Quality Affairs Specialist
  • “Rational Design and Cloning of a Stable RPGR ORF15 cDNA Encoding the Full-Length Native
  • RPGR Protein,” presented by AGTC Associate Scientist Jilin Liu, M.S.

“Safety and Biodistribution Study of rAAV2tYF-PR1.7-hCNGB3 in CNGB3-Deficient Mice,” presented by AGTC Scientist Chunjuan Song, Ph.D.

May 1–5, 2016
12:00 AM
Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)

William A. Beltran, DVM, PhD., Associate Professor of Ophthalmology at the University of Pennsylvania School of Veterinary Medicine, presented new preclinical data evaluating the efficacy of an adeno-associated virus (AAV) vector gene therapy treatment for X-linked retinitis pigmentosa (XLRP), a rare inherited retinal disease that causes progressive vision loss in boys and young men. The abstract is titled "Two AAV2/5-mediated RPGR gene augmentation constructs driven by the GRK1 promoter rescue photoreceptor structure and function in a canine model of RPGR X-linked retinitis pigmentosa."

Additionally, Guo-jie Ye, Ph. D., AGTC Senior Director of Research and Pre-Clinical Studies, presented an abstract titled “Product Development for Gene Therapy of XLRP: Evaluation of Promoters, AAV Capsids in Non-human Primates and Rational Design of RPGR ORF15 cDNA”

Apr 28–29, 2016
Innovation Summit Retinal Cell and Gene Therapy
Seattle
Apr 20–22, 2016
World Orphan Drug Congress USA 2016
Washington, D.C.
Mar 22, 2016
4:05 PM ET
Alliance for Regenerative Medicine's 4th Annual Cell & Gene Therapy Investor Day

Sue Washer, President and CEO, will provide a company presentation on March 22nd at 4:05pm EDT. Ms. Washer will discuss key corporate milestones in addition to reviewing AGTC's clinical pipeline. To access a live webcast of this presentation, please visit http://arminvestorday.com/webcast/. A replay will be available at the same address shortly after the conference.

Mar 21–22, 2016
1:55 PM PT
8th Ocular Diseases Drug Discovery Conference

Mark Shearman, Ph.D., Chief Scientific Officer, will lead a session titled "Clinical Development of rAAV Gene Therapy for Inherited Retinal Disorders," on Monday, March 21st at 1:55pm PDT (4:55pm EDT) where he will discuss the company's ongoing human clinical trials for XLRS and ACHM-B3.

Mar 15, 2016
10:00 AM PT
28th Annual ROTH Conference
Feb 23, 2016
RBC Global Healthcare Conference
Feb 8, 2016
5:00 PM ET
Second Quarter Financial Results Conference Call and Webcast
Feb 1–2, 2016
BMO Capital Markets Healthcare Wintervention
Dec 1, 2015
Piper Jaffray 27th Annual Healthcare Conference

AGTC will be participating in a fireside chat as well as a panel discussion on gene therapy for ophthalmology on December 1, 2015.

Add to Briefcase = add file to Briefcase
Investors